Aaron Ondrey - Apr 1, 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Financial Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Aaron Ondrey
Stock symbol
RCKT
Transactions as of
Apr 1, 2024
Transactions value $
$0
Form type
4
Date filed
4/3/2024, 06:02 PM
Previous filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +46.8K $0.00 46.8K Apr 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCKT Stock Option (Right to Buy) Award $0 +69.3K $0.00 69.3K Apr 1, 2024 Common Stock 69.3K $26.72 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 1, 2025, with the remaining shares vesting in equal quarterly installments over the following two years.
F2 This option represents a right to purchase a total of 69,337 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 1, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.